Literature DB >> 25906392

Principles and challenges in access to experimental medicines.

Michael Rosenblatt1, Bruce Kuhlik1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25906392     DOI： 10.1001/jama.2015.4135

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.

Authors:  Jonathan P Jarow; Steven Lemery; Kevin Bugin; Sean Khozin; Richard Moscicki
Journal:  Ther Innov Regul Sci       Date:  2016-11       Impact factor: 1.778

3.  An analysis of common ethical justifications for compassionate use programs for experimental drugs.

Authors:  Kasper Raus
Journal:  BMC Med Ethics       Date:  2016-10-18       Impact factor: 2.652
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.